Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine versus vinorelbine + chidamide + toripalimab in advanced triple-negative breast cancer
ChiCTR2600135645Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Vinorelbine monotherapy arm with Vinorelbine plus chidamide and toripalimab arm (2 arms). Primary endpoints: Progression-free survival and Incidence and severity of treatment-related adverse events. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
vinorelbinetucidinostattoripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600135645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135645.